EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Similar Long‐Term Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Initiating Entecavir Versus Tenofovir Alafenamide: A REAL ‐B Study

Haruki Uojima iD, Rui Huang, Huy Trinh, Akito Nozaki iD, Philip Vutien, Hidenori Toyoda iD, Takashi Honda, Hiroshi Abe iD, Masanori Atsukawa iD, Tsunamasa Watanabe iD, Toru Ishikawa iD, Masaru Enomoto iD und 16 weitere

Journal of Viral Hepatitis · 2026

DOI: 10.1111/jvh.70250 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Viral Hepatitis, 2026. Verfasst von Haruki Uojima und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Hepatocellular, Guanine, Tenofovir. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data on potential differences in hepatocellular carcinoma (HCC) incidence between entecavir (ETV) and tenofovir alafenamide (TAF) in chronic hepatitis B (CHB) patients are limited. This retrospective multinational study included treatment‐naïve adults with CHB without a history of HCC who initiated ETV or TAF therapy since 2016 at 23 centres in 4 countries. Baseline characteristics were balanced using inverse probability of treatment weighting (IPTW) and propensity score matching (PSM). HCC incidence and the association between antiviral regimen and HCC were analysed using competing‐risk analysis. A total of 1437 patients (710 ETV, 727 TAF) were included, with similar mean follow‐up durations (55.5 ± 29.8 vs. 58.0 ± 25.5 months; p = 0.077). ETV‐treated patients were older, more frequently male, and more likely to have cirrhosis. After IPTW, both groups had balanced characteristics (all standardised differences < 0.1). After IPTW adjustment, during follow‐up, 23 patients on ETV and 20 on TAF developed HCC, with incidence rates of 0.67 and 0.65 per 100 person‐years, respectively ( p = 0.853). There was no statistically significant difference in HCC risk between the groups (SHR: 1.09; 95% CI: 0.44–2.65; p = 0.851), with consistent findings across subgroups by age, sex, cirrhosis, hepatic steatosis, HBeAg, baseline liver enzymes, HBV DNA levels, diabetes mellitus and in sensitivity analysis using PSM. In this real‐world multinational study of treatment‐naïve CHB patients, HCC incidence did not significantly differ between ETV and TAF groups, suggesting therapeutic selection should consider cost and patient‐specific factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicCarcinoma, HepatocellularGuanineTenofovirAntiviral AgentsLiver NeoplasmsAdenineHumansMaleIncidenceRetrospective StudiesMiddle AgedFemaleAlanineAdultAged

Stichwörter der Autor:innen

antiviral regimenhepatocellular carcinoma risklong‐term follow‐upmultinational studynucleos(t)ide analogues

Substanzen

GuanineentecavirTenofovirAntiviral Agentstenofovir alafenamideAlanineAdenine

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, California, USA.
  • Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
  • San Jose Gastroenterology, San Jose, California, USA.
  • Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
  • Division of Gastroenterology and Hepatology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Haruki Uojima, Akito Nozaki, Hidenori Toyoda, Hiroshi Abe, Masanori Atsukawa, Tsunamasa Watanabe, Toru Ishikawa, Masaru Enomoto, Yasuhito Tanaka, Koichi Takaguchi, Pei-Chien Tsai, Wan-Long Chuang, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Mayumi Maeda, Ramsey Cheung, Takanori Ito, Manabu Morimoto, Ming-Lung Yu, Chao Wu, Mindie H Nguyen

Zitieren

APA

Uojima, H., Huang, R., Trinh, H., Nozaki, A., Vutien, P., Toyoda, H., Honda, T., Abe, H., Atsukawa, M., Watanabe, T., Ishikawa, T., Enomoto, M., Tanaka, Y., Takaguchi, K., Tsai, P. C., Chuang, W. L., Dai, C. Y., Huang, J. F., Huang, C. F., …, & Nguyen, M. H. (2026). Similar Long‐Term Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Initiating Entecavir Versus Tenofovir Alafenamide: A REAL ‐B Study. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70250

Vancouver

Uojima H, Huang R, Trinh H, Nozaki A, Vutien P, Toyoda H, et al. Similar Long‐Term Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Initiating Entecavir Versus Tenofovir Alafenamide: A REAL ‐B Study. Journal of Viral Hepatitis. 2026. doi:10.1111/jvh.70250

BibTeX
@article{Uojima2026,
  author = {Uojima, Haruki and Huang, Rui and Trinh, Huy and Nozaki, Akito and Vutien, Philip and Toyoda, Hidenori and Honda, Takashi and Abe, Hiroshi and Atsukawa, Masanori and Watanabe, Tsunamasa and Ishikawa, Toru and Enomoto, Masaru and Tanaka, Yasuhito and Takaguchi, Koichi and Tsai, Pei-Chien and Chuang, Wan-Long and Dai, Chia-Yen and Huang, Jee-Fu and Huang, Chung-Feng and Yeh, Ming-Lun and Senoh, Tomonori and Maeda, Mayumi and Cheung, Ramsey and Ito, Takanori and Morimoto, Manabu and Yu, Ming-Lung and Wu, Chao and Nguyen, Mindie H},
  title = {Similar Long‐Term Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Initiating Entecavir Versus Tenofovir Alafenamide: A REAL ‐B Study},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  doi = {10.1111/jvh.70250}
}
Kostenlos starten →